中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.022 seconds)

    Method for treating an individual suffering from bladder cancer
    41.
    发明授权
    Method for treating an individual suffering from bladder cancer 有权

    公开(公告)号：US11642382B2

    公开(公告)日：2023-05-09

    申请号：US17848759

    申请日：2022-06-24

    Applicant: SEED HEALTH, INC.

    Inventor： Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17 ,  A61K35/00

    CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

    Abstract: A method for treating an individual suffering from bladder cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.

    Method for Treating an Individual Suffering from Bladder Cancer
    43.
    发明申请
    Method for Treating an Individual Suffering from Bladder Cancer 有权

    公开(公告)号：US20220331375A1

    公开(公告)日：2022-10-20

    申请号：US17848759

    申请日：2022-06-24

    Applicant: SEED HEALTH, INC.

    Inventor： Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

    Abstract: A method for treating an individual suffering from bladder cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.

    Topical application to treat acne vulgaris
    44.
    发明授权
    Topical application to treat acne vulgaris 有权

    公开(公告)号：US12246043B2

    公开(公告)日：2025-03-11

    申请号：US18535722

    申请日：2023-12-11

    Applicant: Seed Health, Inc.

    Inventor： Tye Jensen ,  Joseph E. Kovarik ,  Raja Dhir

    IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K35/741 ,  A61K35/745 ,  A61K35/747 ,  A61K38/17 ,  C12N1/20

    Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Embodiments include methods for treating an individual suffering from acne valgaris by topically administering a composition that includes live bacteria selected from the group consisting of L. reuteri, L. johnsonii, L. crispatus, C. acnes, and Nitrosomonas eutropha, that have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the production of a virulence factor of the bacteria.

    Probiotic method and composition for maintaining a healthy vaginal microbiome
    46.
    发明授权
    Probiotic method and composition for maintaining a healthy vaginal microbiome 有权

    公开(公告)号：US12005085B2

    公开(公告)日：2024-06-11

    申请号：US18232433

    申请日：2023-08-10

    Applicant: Seed Health, Inc.

    Inventor： Sheri Simmons ,  Tye Jensen ,  Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K35/00 ,  A61K38/17

    CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

    Abstract: A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of at least two live bacteria selected from the group consisting of L. reuteri, L johnsonii and L. crispatus, and at least one prebiotic having glycogen as a component thereof. The bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina. Certain embodiments include increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina and introducing ammonia oxidizing microorganisms to the individual's vagina.

    Container
    48.
    外观设计
    Container 有权

    公开(公告)号：USD1023764S1

    公开(公告)日：2024-04-23

    申请号：US29831918

    申请日：2022-03-23

    Applicant: Seed Health Inc.

    Designer： Ara Katz ,  Raja Dhir ,  Yuji Sakuma ,  Chelsea Beloff

    Abstract: FIG. 1 is a front perspective view of embodiment one, of a container, showing our new design;
    FIG. 2 is a front elevation view thereof;
    FIG. 3 is a rear elevation thereof;
    FIG. 4 is a right side elevation view thereof;
    FIG. 5 is a left side elevation view thereof;
    FIG. 6 is a top plan view thereof;
    FIG. 7 is a bottom plan view thereof;
    FIG. 8 is a cross-sectional side view thereof taken along line 8-8 shown in FIG. 6;
    FIG. 9 is an exploded side view thereof;
    FIG. 10 is an exploded and cross-sectional side view thereof taken along line 10-10 shown in FIG. 6;
    FIG. 11 is an exploded perspective view thereof;
    FIG. 12 is a front perspective view of embodiment two, of a container, showing our new design;
    FIG. 13 is a front elevation view of the container of FIG. 12;
    FIG. 14 is a rear elevation view of the container of FIG. 12;
    FIG. 15 is a right side elevation view of the container of FIG. 12;
    FIG. 16 is a left side elevation view of the container of FIG. 12;
    FIG. 17 is a top plan view of the container of FIG. 12;
    FIG. 18 is a bottom plan view of the container of FIG. 12;
    FIG. 19 is a cross-sectional side view of the container of FIG. 12 taken along line 19-19 shown in FIG. 17;
    FIG. 20 is an exploded side view of the container of FIG. 12;
    FIG. 21 is an exploded and cross-sectional side view of the container of FIG. 12 taken along line 21-21 shown in FIG. 17;
    FIG. 22 is an exploded perspective view of the container of FIG. 12;
    FIG. 23 is a front perspective view of embodiment three, of a container, showing our new design;
    FIG. 24 is a front elevation view of the container of FIG. 23;
    FIG. 25 is a rear elevation view of the container of FIG. 23;
    FIG. 26 is a right side elevation view of the container of FIG. 23;
    FIG. 27 is a left side elevation view of the container of FIG. 23;
    FIG. 28 is a top plan view of the container of FIG. 23;
    FIG. 29 is a bottom plan view of the container of FIG. 23;
    FIG. 30 is a cross-sectional side view of the container of FIG. 23 taken along line 30-30 shown in FIG. 28;
    FIG. 31 is an exploded side view of the container of FIG. 23;
    FIG. 32 is an exploded and cross-sectional side view of the container of FIG. 23 taken along line 32-32 shown in FIG. 28; and,
    FIG. 33 is an exploded perspective view of the container of FIG. 23.
    The broken lines show portions of the container which form no part of the claimed design.

    Method and System for Reducing the Likelihood of Developing Depression in an Individual
    50.
    发明公开
    Method and System for Reducing the Likelihood of Developing Depression in an Individual 有权

    公开(公告)号：US20230172995A9

    公开(公告)日：2023-06-08

    申请号：US17694775

    申请日：2022-03-15

    Applicant: Seed Health, Inc.

    Inventor： Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

    CPC classification number: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/1758 ,  A61K38/1709 ,  A61K2035/11

    Abstract: A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and L. casei to treat depression.

Patent Agency Ranking